CNC · Centene Corporation · Stock research

Current Thesis

Two sessions have been added since the last update and both closed higher. The reference close is 2026-08-24 at $65.65, 1.0% above the 2026-08-21 close of $65.02 and 2.4% above the 2026-08-20 close of $64.14 — but still 2.7% under the 2026-08-14 close of $67.47, the highest close since the 2026-07-28 print, and 4.5% below the $68.72 52-week high. RSI(14) reads 53.8, mid-range.

The trailing three-month price change now reads +14.8% against +9.9% three sessions earlier. Price itself moved 1.0% across that stretch, so the step-up comes from the measurement window rolling past the late-May lows. That is arithmetic, not fresh demand.

The leg being underwritten is unchanged since 2026-07-28: a shrinking membership book converting a repaired underwriting margin into per-share earnings, with the 2027 volume base unresolved until open enrollment and the December redetermination cycle. Q2 delivered the margin half — adjusted EPS $2.51 against $1.08 consensus, revenue $53.579B against $47.617B consensus, consolidated health benefits ratio 89.6% from 93.0%, FY2026 adjusted guidance lifted to more than $4.80 from more than $3.40. On the same call the CEO said year-end membership would land below the prior outlook.

One scheduling item firms up. Centene's investor-relations events listing carries Q3 2026 results for Tuesday 2026-10-27, 8:30–9:30 a.m. EDT, where the prior read could only cite third-party earnings calendars; no separate press release confirming the date was located as of 2026-08-25. Nothing else company-side has been announced or filed since the 2026-08-17 CFO 8-K.

Theme status: maturing. The post-print revision wave ran 2026-07-29 (Barclays $80, Baird $66, Morgan Stanley $66 from $57) through 2026-08-11 (Argus upgrade to Buy, $80), and has produced no target change in the fourteen days since — the only dated sell-side item is Bernstein's 2026-08-18 Outperform/$79 reiteration written around the CFO change. Coverage is broad, the guidance raise sits in the tape, and the next company-controlled datapoint is 2026-10-27.

Bullish and bearish views on Centene Corporation

The model's bull view on Centene Corporation (CNC), in brief: Q2 2026, reported 2026-07-28: adjusted EPS $2.51 versus $1.08 consensus; revenue $53.579B versus $47.617B consensus; net income $1.09B against a $253M loss a year earlier. The bear view: The membership half of the story is guided down: on 2026-07-28 the CEO said year-end membership would come in below the prior outlook through the back half. Both cases follow in full.

Bull Case

• Q2 2026, reported 2026-07-28: adjusted EPS $2.51 versus $1.08 consensus; revenue $53.579B versus $47.617B consensus; net income $1.09B against a $253M loss a year earlier.
• FY2026 adjusted EPS guidance raised to more than $4.80 from more than $3.40 against $3.52 consensus; revenue guide lifted to $193.5B–$197.5B from $187.5B–$191.5B; GAAP EPS more than $3.11 versus $2.47 consensus (2026-07-28).
• Every segment cost ratio improved in Q2 2026: consolidated HBR 89.6% from 93.0%; Commercial/ACA 79.2% from 90.6%; Medicaid 93.9% from 94.9%; Medicare 89.5% from 90.9%; adjusted SG&A ratio 6.9% versus 7.1%.
• On the 2026-07-28 call the FY2026 Medicaid composite rate forecast moved to roughly 5% from roughly 4.5%, and 2026 marketplace pretax margin was guided to 4.5%–5.0%.
• KFF's 2026-08-03 analysis of 276 insurers filing across all 50 states and DC put the median proposed 2027 marketplace rate change at 15%, with 51 insurers requesting more than 25% — the pricing environment any 2027 margin framework is built on.
• Deleveraging on schedule: $500,000,000 of 4.25% senior notes due 2027-12-15 redeemed at par plus accrued interest on 2026-08-13, leaving roughly $568,664,000 outstanding.
• The bullish end of the panel was set before the print and has not been walked back: Cantor Fitzgerald went to $75 from $60 at Overweight on 2026-07-07 on a payors-over-providers call, and Barclays and Argus both carry $80 marks dated 2026-07-29 and 2026-08-11.

Bear Case

• The membership half of the story is guided down: on 2026-07-28 the CEO said year-end membership would come in below the prior outlook through the back half.
• Roughly $0.50 of the Q2 beat came from prior-year settlement contribution disclosed with the quarter; Q3 on 2026-10-27 is the first period without it.
• Medicaid HBR ran 93.9% in Q2 against the roughly 93.5% target discussed on the call — the segment carrying 12.1M members at 2026-06-30 has not converged yet.
• The GAAP-to-adjusted gap is wide: FY2026 GAAP EPS guided to more than $3.11 against adjusted more than $4.80.
• Insider supply landed into the re-rating: Secretary and General Counsel Christopher Koster sold 47,603 shares on 2026-08-18 at a weighted average $65.36 (range $65.28–$65.45), leaving 305,353.991 shares held directly, on a filing that indicates the sale was not under a Rule 10b5-1 plan.
• The 2027 subsidy environment is still open. The House passed a three-year extension of enhanced premium tax credits 230-196 on 2026-01-08 and no enacted Senate action has followed; ASTHO's legislative tracker describes a bipartisan Senate group circulating a two-year alternative with minimum premium payments and income caps.
• WSJ reported on 2026-07-28 that the Medicare drug-plan premium stabilization program was not renewed for 2027, a 2027 margin headwind inside a book whose 2026 margin guide was just raised.
• Target panels are dispersed rather than converged: stockanalysis.com showed an average of $71.67 across 21 analysts with a Hold consensus (8 buy / 12 hold / 1 sell) as of 2026-08-23, against aggregator averages near $61 elsewhere and a published range spanning roughly $39–$40 to $80.

Setup & Price Structure

The post-print sequence of closes is now $67.47 (2026-08-14) → $64.14 (2026-08-20) → $65.02 (2026-08-21) → $65.65 (2026-08-24). That is a roughly $64–$67.50 band over seven sessions, with the 2026-08-14 high close still unrecovered and the $68.72 52-week high 4.5% away. RSI(14) at 53.8 shows no momentum extension in either direction.

Positioning observables, stated as observed:

• Insider selling struck inside the current band on 2026-08-18 at $65.28–$65.45, not under a 10b5-1 plan (Form 4, CIK 0001071739).
• No earnings date sits inside 30 days; the print is 2026-10-27, so there is no imminent binary compressing the tape.
• Retail-facing coverage in the last fortnight has clustered on the Mark Cuban insurer-divestment campaign (2026-08-11) and the follow-on ETF-exposure piece (2026-08-14) rather than on fundamentals — attention with a negative flow bias.
• The sell-side revision impulse has stopped: last target change 2026-08-11, one reiteration since (2026-08-18).

The structural marker for a resumed leg is a weekly close back above $67.47, and beyond that $68.72. Below, the July range floor and the $63 area define where the post-print sequence breaks.

Catalyst Calendar (next 30 days)

• 2026-09-08 to 2026-09-10 — Wells Fargo healthcare conference window (Wells Fargo materials show 2026-09-09 as a conference day; Boston Scientific's 2026-08-10 notice dates its own appearance to September 10). Centene participation was not announced as of 2026-08-25. This is the only plausible mid-quarter venue for incremental 2027 marketplace and Medicaid rate commentary.
• ~2026-09-30 (est.) — Incoming CFO Chris Neczypor joins ahead of the 2027-01-01 handover, per the 2026-08-17 release; a start would be marked by a Form 3 or an 8-K.
• Beyond the 30-day window, the next hard dates are 2026-10-15 (outer PY2027 QHP filing deadline for state-based exchanges not on HealthCare.gov), 2026-10-27 (Q3 2026 results, 8:30–9:30 a.m. EDT per the company's investor-relations listing), and ~2026-11-01 (est.) (2027 open enrollment begins).

What Would Change Our Mind

The cleanest break in this frame is structural: the 2026-08-14 close of $67.47 has been rejected once, and a second failure that carries price out the bottom of the band ends the post-print sequence. The gradeable version is a weekly close below $63; a weekly close below $56 would surrender the July range outright. On the other side, a weekly close above $68.72 accompanied by a fresh target raise — none has been issued since 2026-08-11 — would argue the theme is re-accelerating rather than maturing.

On fundamentals, the read changes if the September 8–10 conference window passes with no Centene appearance and no incremental 2027 rate commentary while price stays under $67.47, or if Q3 on 2026-10-27 shows Medicaid HBR at or above the 93.9% Q2 level, or any softening of the more-than-$4.80 FY2026 adjusted guide, with the roughly $0.50 prior-year settlement contribution absent from the quarter.

Correlation Notes

• The managed-care complex marks on enrollment rather than earnings: Molina beat and closed -12% on 2026-07-23, and Centene closed -5.1% on its own beat-and-raise day 2026-07-28. A peer print can move this chart with no company news.
• Policy is the larger correlated driver. CMS reported 23.1M plan selections for 2026, roughly 1.2M below 2025, and projects its 2027 payment-parameters rule alone cuts enrollment by 1.2–2M; the Urban Institute estimated on 2026-07-16 that 2–3.1M people could lose Medicaid coverage in the twice-yearly redetermination cycle starting around 2026-12-01. Revenue is set largely by state rate cycles and CMS rulemaking.
• Premium and service revenue ran $44.4B in Q2 2026 on a thin underwriting spread, so a point of HBR moves EPS more than membership headlines do — the sector's reaction function and the P&L's sensitivity point in different directions.
• Index and ETF ownership is the transmission channel for the divestment campaign coverage of 2026-08-11 and 2026-08-14; broad-market funds hold the name regardless of the fundamental debate.